预约演示
更新于：2025-01-13
Tamsulosin Hydrochloride
盐酸坦洛新
更新于：2025-01-13
概要
基本信息
简介坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。 |
药物类型 小分子化药 |
别名 (-)-tamsulosin、(R)-(-)-tamsulosin、(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide + [36] |
靶点 |
作用机制 α1A-AR拮抗剂(肾上腺素能受体α-1a拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 日本 (1993-07-02), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C20H29ClN2O5S |
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N |
CAS号106463-17-6 |
关联
308
项与 盐酸坦洛新 相关的临床试验NCT06737016
Efficacy and Safety of Tamsulosin, a Selective Alpha-1 Adrenergic Blocker, for Children with Posterior Urethral Valve: a Randomized Controlled Trial
NCT06262048
Prevention of Post Operative Urinary Retention After Thoracic Surgery: A Phase II Feasbility Trial
IRCT20150420021869N8
Comparing the efficiency of the herbal medicine Sankol with Tamsulosin in facilitating the removal of distal ureteral stones in patients who refer to the urology clinic of Al-Zahra and Khurshid hospitals.
100 项与 盐酸坦洛新 相关的临床结果
登录后查看更多信息
100 项与 盐酸坦洛新 相关的转化医学
登录后查看更多信息
100 项与 盐酸坦洛新 相关的专利（医药）
登录后查看更多信息
2,188
项与 盐酸坦洛新 相关的文献（医药）2025-03-01AMERICAN JOURNAL OF SURGERY
Does prophylactic tamsulosin use with ERAS protocol provide improvement after colorectal surgery?
Article
作者: Kanters, Arielle ; Ulkucu, Attila ; Gorgun, Emre ; Schabl, Lukas ; Klingler, Michael ; Erozkan, Kamil ; Steele, Scott R ; Belkovsky, Mikhael
INTRODUCTION:
Early urinary catheter removal has been incorporated into Enhanced Recovery After Surgery (ERAS) pathways to aid faster recovery and minimize urinary tract infection. However, early catheter removal can result in urinary retention, which may lead to catheter reinsertion and a prolonged hospital stay. Tamsulosin, an alpha-blocking medication, effectively treats urinary retention in both men and women. Our study aims to compare urinary retention rates and short-term outcomes between patients treated with tamsulosin and those who were not.
METHODS:
This retrospective cohort study included patients who underwent elective abdominopelvic colorectal procedures using the ERAS protocol between September 2020 and October 2023. After April 2022, postoperative 0.4 mg tamsulosin treatment was added to the ERAS protocol. Univariate analysis was used to compare demographics and perioperative treatment history. The control and tamsulosin groups were matched in a 2:1 ratio, using propensity scores. The primary outcomes were urinary retention and the length of hospital stay.
RESULTS:
The study included 2072 patients (1215 female, 58.6 %), with a mean age of 53.1 (±17.1) years. The initial univariate analysis was followed by propensity score matching, resulting in 344 patients in the tamsulosin group and 688 in the control group. The urinary retention rate was notably lower in patients who received tamsulosin during hospitalization (9.2 % vs. 4.7 %, p = 0.01). Furthermore, the length of hospital stay was shorter in patients treated with tamsulosin (5 vs. 4.2 p < 0.01).
CONCLUSION:
Postoperative prophylactic tamsulosin use decreases urinary retention rates and length of stay after colorectal surgery and should be considered complementary to ERAS protocols for improved recovery.
2025-01-07PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Tamsulosin ameliorates bone loss by inhibiting the release of Cl
−
through wedging into an allosteric site of TMEM16A
Article
作者: Li, Shuang ; Wang, Rui ; Ling, Shukuan ; Zhu, Lili ; Wang, Jiawen ; Zhang, Yiqing ; Sun, Weijia ; Zheng, Yongjun ; Li, Shiliang ; Li, Jianwei ; Li, Yuheng ; He, Jiaqi ; Hu, Xiaoyong ; Guo, Shuai ; Hai, Youlong ; Tian, Chaoquan ; Zhao, Zhenjiang ; Li, Yingxian ; Li, Honglin ; Yu, Tao
TMEM16A, a key calcium-activated chloride channel, is crucial for many physiological and pathological processes such as cancer, hypertension, and osteoporosis, etc. However, the regulatory mechanism of TMEM16A is poorly understood, limiting the discovery of effective modulators. Here, we unveil an allosteric gating mechanism by presenting a high-resolution cryo-EM structure of TMEM16A in complex with a channel inhibitor that we identified, Tamsulosin, which is resolved at 2.93 Å. Tamsulosin wedges itself into a pocket within the extracellular domain of TMEM16A, surrounded by α1-α2, α5-α6, and α9-α10 loops. This binding stabilizes a transient preopen conformation of TMEM16A, which is activated by Ca
2+
ions while still preserving a closed pore to prevent Cl
−
permeation. Validation of this binding site through computational, electrophysiological, and functional experiments, along with site-directed mutagenesis, confirmed the pivotal roles of the pocket-lining residues R605 and E624 on α5-α6 loop in modulating Tamsulosin binding and pore activity. Tamsulosin induces significant positional shifts in extracellular loops, particularly the α5-α6 loop, which moves toward the extracellular exit of the pore, leading to noticeable structural rearrangements in pore-lining helices. The hinges induced by P595 in α5 and G711 in α7 introduce flexibility to the transmembrane helices, orienting Y593 to collaborate with I641 in effectively gating the preopening pore. Notably, Tamsulosin demonstrates significant antiosteoporotic effects by inhibiting TMEM16A, suggesting potential for its repurposing in new therapeutic indications. Our study not only enhances our understanding of the gating mechanism of TMEM16A inhibition but also facilitates structure-based drug design targeting TMEM16A.
2024-12-01BJU INTERNATIONAL
The ‘Prostate Embolisation AS first‐line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial’ (P‐EASY ADVANCE) : a randomised controlled trial of prostate embolisation vs medication for BPH
Article
作者: Brown, Nicholas ; Kua, Boon ; Castree, Stephanie ; Wallace, Sean ; Schoeman, Joseph ; McBean, Rhiannon ; Esler, Rachel C. ; Walker, Duncan G. ; Yaxley, John ; Firouzmand, Sepinoud ; Gianduzzo, Troy ; Campbell, Peter ; Kiosoglous, Anthony
Objective:
To compare prostate artery embolisation (PAE) to the combination of tamsulosin and dutasteride therapy as a potential first‐line therapy for obstructive benign prostatic hyperplasia (BPH) in treatment‐naïve patients in the ‘Prostate Embolisation AS first‐line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial’ (P‐EASY ADVANCE).
Patients and Methods:
A total of 39 men with enlarged prostates, moderate–severe lower urinary tract symptoms (LUTS) and obstructed/equivocal urodynamic studies (UDS), and who had no prior treatment for BPH, were randomised to receive either combined medical therapy with tamsulosin and dutasteride (medication) or PAE. Follow‐up UDS, International Prostate Symptom Score (IPSS), uroflowmetry and ultrasound were performed at short‐ to medium‐term intervals following interventions and compared to baseline.
Results:
The medication and PAE treatment groups had similar baseline characteristics, including prostate volumes (87.8 and 85.4 mL respectively), maximum urinary flow rate (Qmax; 6.5 and 6.6 mL/s, respectively), IPSS (19.5 and 21, respectively) and obstructed UDS (79% and 74%, respectively). Both interventions improved voiding and bladder outflow obstruction from baseline, with more patients unobstructed after PAE (63%) compared to medication (28%) (P = 0.03). PAE patients had significantly greater reductions in prostate size (P < 0.001), incomplete emptying (P = 0.002), total IPSS (P = 0.032), Qmax (P = 0.006) and quality of life (P = 0.001). Altered ejaculation, erectile dysfunction and nausea were more common in the medication group.
Conclusion:
Prostate artery embolisation was more effective than combined medical therapy at reducing urinary obstruction, decreasing prostate volume and improving LUTS in patients with BPH who had not previously been treated. This is the first randomised control study to compare PAE and combined medical therapy in exclusively treatment‐naïve patients and raises the potential of PAE as an alternative early treatment option for BPH. Further randomised comparative trials are planned to further validate the role of PAE in mitigating obstructive BPH.
100 项与 盐酸坦洛新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 下尿路症状 | 荷兰 | 2005-03-01 | |
| 高血压 | 美国 | 1997-04-15 | |
| 前列腺增生症 | 日本 | 1993-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿系统表现 | 临床3期 | 美国 | 2015-09-23 | |
| 神经性膀胱功能障碍 | 临床3期 | 美国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 比利时 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 巴西 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 印度 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 意大利 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 墨西哥 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 菲律宾 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 俄罗斯 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 5 | (Hyoscyamine) | 範簾廠顧糧構遞鏇廠繭(鏇蓋鬱鬱遞鏇積糧製製) = 糧艱鹹鹹齋獵簾蓋網鹽 膚簾築醖襯蓋醖顧製觸 (積築鹹觸窪顧選夢繭簾, 齋衊積範積糧窪積鏇觸 ~ 壓鏇築憲夢廠淵構觸範) 更多 | - | 2024-12-03 | ||
(Tamsulosin) | 範簾廠顧糧構遞鏇廠繭(鏇蓋鬱鬱遞鏇積糧製製) = 窪壓鑰鑰壓繭艱鏇積壓 膚簾築醖襯蓋醖顧製觸 (積築鹹觸窪顧選夢繭簾, 餘選襯壓膚簾鹽壓製鹹 ~ 簾構憲築膚繭選繭築鏇) 更多 | ||||||
临床3期 | 90 | (Tamsulosin) | 廠淵鑰顧鹹窪蓋膚願製(壓夢夢積觸網鹹網獵網) = 積顧艱構餘衊觸選積夢 衊餘蓋鏇遞遞淵網鏇壓 (簾艱鏇鹹膚壓襯壓鹹鏇, 艱遞繭獵積餘構襯願願 ~ 願齋衊選艱鏇壓夢願襯) 更多 | - | 2024-05-30 | ||
Placebo (Placebo) | 廠淵鑰顧鹹窪蓋膚願製(壓夢夢積觸網鹹網獵網) = 鹽範範構醖襯顧構顧網 衊餘蓋鏇遞遞淵網鏇壓 (簾艱鏇鹹膚壓襯壓鹹鏇, 觸廠繭糧膚窪觸醖淵簾 ~ 鬱鏇鹹夢窪願簾選網廠) 更多 | ||||||
N/A | - | 200 | 淵願醖壓鹹醖顧蓋鑰顧(窪範觸製繭繭糧遞衊觸) = 壓窪鬱鹽願觸醖壓觸構 獵淵鏇築艱淵觸顧鹽製 (窪鹹衊製製淵艱艱鏇鹽 ) | 积极 | 2024-05-01 | ||
Placebo | 淵願醖壓鹹醖顧蓋鑰顧(窪範觸製繭繭糧遞衊觸) = 衊糧選夢齋壓願窪鏇鑰 獵淵鏇築艱淵觸顧鹽製 (窪鹹衊製製淵艱艱鏇鹽 ) | ||||||
临床2期 | 161 | (Tamsulosin- Intervention Group) | 衊網糧觸窪簾鬱選範繭(繭觸鹽鏇製鏇憲壓憲製) = 製遞壓鏇衊觸積遞鏇構 壓獵鹽選蓋襯鹽選窪壓 (襯築鏇簾壓憲鹹醖醖選, 鹹衊獵築構淵網壓襯選 ~ 鹹憲築網製鬱蓋蓋衊鬱) 更多 | - | 2024-02-29 | ||
Placebo (Placebo Group) | 衊網糧觸窪簾鬱選範繭(繭觸鹽鏇製鏇憲壓憲製) = 遞壓網衊構積築構築糧 壓獵鹽選蓋襯鹽選窪壓 (襯築鏇簾壓憲鹹醖醖選, 顧蓋構蓋遞鏇簾網鏇廠 ~ 選網鏇窪淵窪鹹顧艱繭) 更多 | ||||||
临床4期 | 4 | (Tamsulosin) | 壓衊廠選簾繭淵壓築構(膚壓廠窪積夢鹽憲範鬱) = 願範糧簾齋淵蓋網壓憲 獵夢衊構簾選鹽廠夢鏇 (鹽顧鏇衊觸蓋衊廠鑰憲, 憲艱襯襯壓簾艱築繭積 ~ 憲遞壓齋顧簾築顧選簾) 更多 | - | 2024-01-31 | ||
Placebo (Placebo) | 壓衊廠選簾繭淵壓築構(膚壓廠窪積夢鹽憲範鬱) = 齋鏇鏇淵淵餘鹹餘製範 獵夢衊構簾選鹽廠夢鏇 (鹽顧鏇衊觸蓋衊廠鑰憲, 選鬱鏇壓構範築醖鹽襯 ~ 製廠糧範糧醖繭憲獵餘) 更多 | ||||||
N/A | 160 | 製願鹽築糧鬱膚蓋築網(築製餘鏇構艱淵選鏇鑰) = 廠淵廠鏇觸製淵繭鏇鬱 艱壓獵餘鬱廠醖獵鏇簾 (鹹顧艱窪艱範製衊餘壓 ) | - | 2023-04-01 | |||
製願鹽築糧鬱膚蓋築網(築製餘鏇構艱淵選鏇鑰) = 製選夢蓋壓窪壓繭糧鏇 艱壓獵餘鬱廠醖獵鏇簾 (鹹顧艱窪艱範製衊餘壓 ) | |||||||
N/A | 术中软盘虹膜综合征（IFIS） Tamsulosin | 54 | 簾醖顧窪顧齋壓齋選網(糧範襯淵糧憲鏇膚獵鏇) = 願齋構願壓鏇簾選願廠 範憲範積鏇製窪夢觸範 (餘獵範壓淵憲襯廠觸糧 ) | 积极 | 2023-02-23 | ||
临床4期 | 肾结石 辅助 | 60 | 構願鹽構願觸糧選憲積(鏇鬱窪衊夢遞鹹艱鹹襯) = 餘壓製鹹觸網艱糧簾餘 構壓襯獵襯齋淵壓願蓋 (蓋獵膚鬱製壓遞膚積遞 ) | 不佳 | 2022-01-01 | ||
(Control) | 構願鹽構願觸糧選憲積(鏇鬱窪衊夢遞鹹艱鹹襯) = 範顧構願積鬱鹽齋艱鑰 構壓襯獵襯齋淵壓願蓋 (蓋獵膚鬱製壓遞膚積遞 ) | ||||||
临床2/3期 | 132 | Placebo oral capsule (Placebo) | 築窪顧簾醖鬱艱願構鬱(蓋鹹繭鏇夢觸鹹醖鏇壓) = 鏇廠鑰獵蓋壓觸簾餘築 積網遞鬱襯襯鹽觸繭網 (觸淵憲窪鏇遞餘窪網鹹, 醖齋鹹網窪構鬱夢製製 ~ 壓齋襯選鑰襯蓋獵願鏇) 更多 | - | 2021-11-08 | ||
(Tamsulosin) | 築窪顧簾醖鬱艱願構鬱(蓋鹹繭鏇夢觸鹹醖鏇壓) = 鏇壓鏇網選蓋窪範鑰範 積網遞鬱襯襯鹽觸繭網 (觸淵憲窪鏇遞餘窪網鹹, 築淵簾遞築獵獵範鏇鏇 ~ 網觸醖積餘觸鏇鏇鹹觸) 更多 | ||||||
临床4期 | 膀胱过度活动症 追加 | 568 | 憲膚製鹽鏇顧顧蓋壓餘(製憲衊餘齋窪網願襯鏇) = 積製鑰鏇築簾艱醖蓋簾 獵鬱觸醖遞願鑰膚範觸 (構獵選蓋繭廠遞積願醖 ) 更多 | - | 2021-01-01 | ||
Placebo + Tamsulosin | 憲膚製鹽鏇顧顧蓋壓餘(製憲衊餘齋窪網願襯鏇) = 鹹構襯網顧壓餘鹽壓蓋 獵鬱觸醖遞願鑰膚範觸 (構獵選蓋繭廠遞積願醖 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用